In a report released today, Michael Petusky from Barrington maintained a Buy rating on BioScrip Inc (NASDAQ: BIOS), with a price target of $4. The company’s shares opened today at $3.10, close to its 52-week high of $3.26.
Petusky wrote:
“We continue to rate BIOS shares an OUTPERFORM and our price target is $4. We arrive at our price target by attaching a 14x multiple to our 2019 adjusted EBITDA estimate. We assume approximately $550 million in net debt (including pfd stock) 12 months from now. Company Description BioScrip, Inc. is a leading national provider of infusion and home healthcare management solutions. BioScrip partners with healthcare providers, including physicians, hospital systems, skilled nursing facilities, and with healthcare payors to provide patients better access to high quality, efficient post‐acute care services. BioScrip operates with a commitment to bring infusion therapy services into the home or alternate‐site settings.”
According to TipRanks.com, Petusky is a 4-star analyst with an average return of 14.2% and a 59.2% success rate. Petusky covers the Healthcare sector, focusing on stocks such as Anika Therapeutics Inc, Varian Medical Systems, and DENTSPLY SIRONA Inc.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for BioScrip Inc with a $3.75 average price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $3.26 and a one-year low of $1.80. Currently, BioScrip Inc has an average volume of 501.3K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
BioScrip, Inc. engages in the provision of home infusion and home care management solutions. It partners with physicians, hospital systems, skilled nursing facilities, healthcare payors, and pharmaceutical manufacturers to provide patients access to post-acute care services.
